Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
DOI: | 10.33448/rsd-v11i6.29198 |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/29198 |
Resumo: | Introduction: azithromycin was one of the most employed medications during the beginning of the SARS-CoV2 pandemic, despite the lack of scientific basis for its use treatment of COVID-19. Its uncontrolled adoption has risen as a public health problem, as it promotes the appearance of drug-resistant bacterial strains, making it difficult to effectively treat many bacterial infections. Objective: to understand the implications of bacterial resistance to azithromycin in the treatment of infections in the fight against COVID-19. Methods: we surveyed a total of 38 scientific articles. The inclusion criteria were: studies whose central theme was bacterial resistance to azithromycin in the treatment of bacterioses and azithromycin in the fight against COVID-19, published from 2015 to 2022. Results: the widespread use of antibiotics may act in the selection of bacterial strains which had long held genetic traits for drug resistance, but which, not representing adaptative advantages, did not proliferate in the subsequent lineages. This direct proportionality between the widespread use and bacterial resistance to azithromycin is yet more aggravated in COVID-19 times, when part of the medical community and layman population self-medicates with azithromycin, without a scientific basis that justifies choosing this drug. Conclusion: there is a direct relationship between the indiscriminate use of azithromycin and a potential bacterial resistance to this drug. The appearance of resistant bacteria represents a serious public health problem due to the broad use of azithromycin against several bacterial infections. |
id |
UNIFEI_d050d501f5bface0223ab8db9ba6b20e |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/29198 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
spelling |
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19Resistencia bacteriana a la azitromicina: causas, efectos y la lucha contra el COVID-19Resistência bacteriana à azitromicina: causas, efeitos e combate ao COVID-19AzithromycinAntibacterial Drug ResistanceCOVID-19Virology.AzitromicinaFarmacorresistencia BacterianaCOVID-19Virología.AzitromicinaFarmacorresistência BacterianaCOVID-19Virologia.Introduction: azithromycin was one of the most employed medications during the beginning of the SARS-CoV2 pandemic, despite the lack of scientific basis for its use treatment of COVID-19. Its uncontrolled adoption has risen as a public health problem, as it promotes the appearance of drug-resistant bacterial strains, making it difficult to effectively treat many bacterial infections. Objective: to understand the implications of bacterial resistance to azithromycin in the treatment of infections in the fight against COVID-19. Methods: we surveyed a total of 38 scientific articles. The inclusion criteria were: studies whose central theme was bacterial resistance to azithromycin in the treatment of bacterioses and azithromycin in the fight against COVID-19, published from 2015 to 2022. Results: the widespread use of antibiotics may act in the selection of bacterial strains which had long held genetic traits for drug resistance, but which, not representing adaptative advantages, did not proliferate in the subsequent lineages. This direct proportionality between the widespread use and bacterial resistance to azithromycin is yet more aggravated in COVID-19 times, when part of the medical community and layman population self-medicates with azithromycin, without a scientific basis that justifies choosing this drug. Conclusion: there is a direct relationship between the indiscriminate use of azithromycin and a potential bacterial resistance to this drug. The appearance of resistant bacteria represents a serious public health problem due to the broad use of azithromycin against several bacterial infections.Introducción: la azitromicina fue uno de los medicamentos más empleados durante el inicio de la pandemia por SARS-CoV2, a pesar de la falta de base científica para su uso en el tratamiento de la COVID-19. Su adopción descontrolada se ha convertido en un problema de salud pública, ya que favorece la aparición de cepas bacterianas resistentes a los medicamentos, lo que dificulta el tratamiento eficaz de muchas infecciones bacterianas. Objetivo: comprender las implicaciones de la resistencia bacteriana a la azitromicina en el tratamiento de infecciones en la lucha contra la COVID-19. Métodos: se encuestaron un total de 38 artículos científicos. Los criterios de inclusión fueron: estudios cuyo tema central fuera la resistencia bacteriana a la azitromicina en el tratamiento de bacteriosis y azitromicina en la lucha contra el COVID-19, publicados de 2015 a 2022. Resultados: el uso generalizado de antibióticos puede actuar en la selección de cepas bacterianas que había tenido durante mucho tiempo rasgos genéticos para la resistencia a los medicamentos, pero que, al no representar ventajas adaptativas, no proliferaron en los linajes posteriores. Esta proporcionalidad directa entre el uso generalizado y la resistencia bacteriana a la azitromicina se agrava aún más en tiempos de COVID-19, cuando parte de la comunidad médica y la población profana se automedica con azitromicina, sin una base científica que justifique la elección de este fármaco. Conclusión: existe una relación directa entre el uso indiscriminado de azitromicina y una potencial resistencia bacteriana a este fármaco. La aparición de bacterias resistentes representa un grave problema de salud pública debido al amplio uso de la azitromicina contra diversas infecciones bacterianas.Introdução: a azitromicina foi um dos medicamentos mais empregados durante o início da pandemia de SARS-CoV2, apesar da falta de embasamento científico para seu uso no tratamento da COVID-19. Sua adoção descontrolada tem se tornado um problema de saúde pública, pois promove o aparecimento de cepas bacterianas resistentes aos medicamentos, dificultando o tratamento eficaz de muitas infecções bacterianas. Objetivo: compreender as implicações da resistência bacteriana à azitromicina no tratamento de infecções no combate à COVID-19. Métodos: pesquisamos um total de 38 artigos científicos. Os critérios de inclusão foram: estudos cujo tema central fosse resistência bacteriana à azitromicina no tratamento de bacterioses e azitromicina no combate à COVID-19, publicados de 2015 a 2022. Resultados: o uso generalizado de antibióticos pode atuar na seleção de cepas bacterianas que detinham por muito tempo traços genéticos para resistência a drogas, mas que, não representando vantagens adaptativas, não proliferaram nas linhagens subsequentes. Essa proporcionalidade direta entre o uso generalizado e a resistência bacteriana à azitromicina é ainda mais agravada em tempos de COVID-19, quando parte da comunidade médica e população leiga se automedicam com azitromicina, sem base científica que justifique a escolha desse medicamento. Conclusão: existe uma relação direta entre o uso indiscriminado de azitromicina e uma potencial resistência bacteriana a esta droga. O aparecimento de bactérias resistentes representa um grave problema de saúde pública devido ao amplo uso da azitromicina contra diversas infecções bacterianas.Research, Society and Development2022-04-27info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2919810.33448/rsd-v11i6.29198Research, Society and Development; Vol. 11 No. 6; e27711629198Research, Society and Development; Vol. 11 Núm. 6; e27711629198Research, Society and Development; v. 11 n. 6; e277116291982525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/29198/25211Copyright (c) 2022 Raylton Jansen e Silva Segundo; Júlia Passos Rufino; Lunalva Gabrielli Veras Sousa; Anna Eduarda Linhares Rodrigues; Anna Lira Soares Falcão; Isabelle Carvalho de Melo Lima; Lívia Ayres de Miranda Cavalcanti ; Ana Carolina Soares Dias; José Williams Gomes de Oliveira Filhohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva Segundo, Raylton Jansen eRufino, Júlia PassosSousa, Lunalva Gabrielli VerasRodrigues, Anna Eduarda LinharesFalcão, Anna Lira SoaresLima, Isabelle Carvalho de MeloCavalcanti , Lívia Ayres de Miranda Dias, Ana Carolina SoaresOliveira Filho, José Williams Gomes de2022-05-13T18:04:10Zoai:ojs.pkp.sfu.ca:article/29198Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:46:20.603777Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 Resistencia bacteriana a la azitromicina: causas, efectos y la lucha contra el COVID-19 Resistência bacteriana à azitromicina: causas, efeitos e combate ao COVID-19 |
title |
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 |
spellingShingle |
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 Silva Segundo, Raylton Jansen e Azithromycin Antibacterial Drug Resistance COVID-19 Virology. Azitromicina Farmacorresistencia Bacteriana COVID-19 Virología. Azitromicina Farmacorresistência Bacteriana COVID-19 Virologia. Silva Segundo, Raylton Jansen e Azithromycin Antibacterial Drug Resistance COVID-19 Virology. Azitromicina Farmacorresistencia Bacteriana COVID-19 Virología. Azitromicina Farmacorresistência Bacteriana COVID-19 Virologia. |
title_short |
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 |
title_full |
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 |
title_fullStr |
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 |
title_full_unstemmed |
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 |
title_sort |
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19 |
author |
Silva Segundo, Raylton Jansen e |
author_facet |
Silva Segundo, Raylton Jansen e Silva Segundo, Raylton Jansen e Rufino, Júlia Passos Sousa, Lunalva Gabrielli Veras Rodrigues, Anna Eduarda Linhares Falcão, Anna Lira Soares Lima, Isabelle Carvalho de Melo Cavalcanti , Lívia Ayres de Miranda Dias, Ana Carolina Soares Oliveira Filho, José Williams Gomes de Rufino, Júlia Passos Sousa, Lunalva Gabrielli Veras Rodrigues, Anna Eduarda Linhares Falcão, Anna Lira Soares Lima, Isabelle Carvalho de Melo Cavalcanti , Lívia Ayres de Miranda Dias, Ana Carolina Soares Oliveira Filho, José Williams Gomes de |
author_role |
author |
author2 |
Rufino, Júlia Passos Sousa, Lunalva Gabrielli Veras Rodrigues, Anna Eduarda Linhares Falcão, Anna Lira Soares Lima, Isabelle Carvalho de Melo Cavalcanti , Lívia Ayres de Miranda Dias, Ana Carolina Soares Oliveira Filho, José Williams Gomes de |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Silva Segundo, Raylton Jansen e Rufino, Júlia Passos Sousa, Lunalva Gabrielli Veras Rodrigues, Anna Eduarda Linhares Falcão, Anna Lira Soares Lima, Isabelle Carvalho de Melo Cavalcanti , Lívia Ayres de Miranda Dias, Ana Carolina Soares Oliveira Filho, José Williams Gomes de |
dc.subject.por.fl_str_mv |
Azithromycin Antibacterial Drug Resistance COVID-19 Virology. Azitromicina Farmacorresistencia Bacteriana COVID-19 Virología. Azitromicina Farmacorresistência Bacteriana COVID-19 Virologia. |
topic |
Azithromycin Antibacterial Drug Resistance COVID-19 Virology. Azitromicina Farmacorresistencia Bacteriana COVID-19 Virología. Azitromicina Farmacorresistência Bacteriana COVID-19 Virologia. |
description |
Introduction: azithromycin was one of the most employed medications during the beginning of the SARS-CoV2 pandemic, despite the lack of scientific basis for its use treatment of COVID-19. Its uncontrolled adoption has risen as a public health problem, as it promotes the appearance of drug-resistant bacterial strains, making it difficult to effectively treat many bacterial infections. Objective: to understand the implications of bacterial resistance to azithromycin in the treatment of infections in the fight against COVID-19. Methods: we surveyed a total of 38 scientific articles. The inclusion criteria were: studies whose central theme was bacterial resistance to azithromycin in the treatment of bacterioses and azithromycin in the fight against COVID-19, published from 2015 to 2022. Results: the widespread use of antibiotics may act in the selection of bacterial strains which had long held genetic traits for drug resistance, but which, not representing adaptative advantages, did not proliferate in the subsequent lineages. This direct proportionality between the widespread use and bacterial resistance to azithromycin is yet more aggravated in COVID-19 times, when part of the medical community and layman population self-medicates with azithromycin, without a scientific basis that justifies choosing this drug. Conclusion: there is a direct relationship between the indiscriminate use of azithromycin and a potential bacterial resistance to this drug. The appearance of resistant bacteria represents a serious public health problem due to the broad use of azithromycin against several bacterial infections. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-04-27 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/29198 10.33448/rsd-v11i6.29198 |
url |
https://rsdjournal.org/index.php/rsd/article/view/29198 |
identifier_str_mv |
10.33448/rsd-v11i6.29198 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/29198/25211 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 6; e27711629198 Research, Society and Development; Vol. 11 Núm. 6; e27711629198 Research, Society and Development; v. 11 n. 6; e27711629198 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1822178641249828864 |
dc.identifier.doi.none.fl_str_mv |
10.33448/rsd-v11i6.29198 |